应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02096 先声药业
休市中 08-23 16:08:27
5.280
+0.040
+0.76%
最高
5.300
最低
5.080
成交量
379.30万
今开
5.300
昨收
5.240
日振幅
4.20%
总市值
134.31亿
流通市值
133.42亿
总股本
25.44亿
成交额
1,967万
换手率
0.15%
流通股本
25.27亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
先声药业(02096.HK):1H24经调整利润略超预期 关注创新放量
中金公司 · 12:51
先声药业(02096.HK):1H24经调整利润略超预期 关注创新放量
先声药业(02096)8月23日斥资1021.48万港元回购196万股
智通财经 · 08-23 18:24
先声药业(02096)8月23日斥资1021.48万港元回购196万股
先声药业(02096.HK)抗肿瘤候选药获准开展临床试验
阿斯达克财经 · 08-23 01:36
先声药业(02096.HK)抗肿瘤候选药获准开展临床试验
先声药业(02096.HK):SIM0508(Polθ小分子抑制剂)获国家药品监督管理局签发药物临床试验批准通知书
格隆汇 · 08-22 20:17
先声药业(02096.HK):SIM0508(Polθ小分子抑制剂)获国家药品监督管理局签发药物临床试验批准通知书
先声药业(02096)自主研发的抗肿瘤候选药物-DNA聚合酶θ(Polθ)小分子抑制剂SIM0508获批开展临床试验
智通财经 · 08-22 20:15
先声药业(02096)自主研发的抗肿瘤候选药物-DNA聚合酶θ(Polθ)小分子抑制剂SIM0508获批开展临床试验
先声药业(02096)授出合共296.81万份受限制股份单位
智通财经 · 08-22 18:45
先声药业(02096)授出合共296.81万份受限制股份单位
港股药品股多数下跌,石药集团(01093.HK)跌超8%,石四药集团(02005.HK)跌超3%,先声药业(02096.HK)、联邦制药(03933.
美港电讯 · 08-22
港股药品股多数下跌,石药集团(01093.HK)跌超8%,石四药集团(02005.HK)跌超3%,先声药业(02096.HK)、联邦制药(03933.
先声药业:2024年上半年收入31.14亿元,同比下降7.9%,创新药业务收入占比70.7%
华尔街见闻 · 08-22
先声药业:2024年上半年收入31.14亿元,同比下降7.9%,创新药业务收入占比70.7%
先声药业公布中期业绩 经调整净利约5.38亿元同比增长约36.5%
新浪港股 · 08-22
先声药业公布中期业绩 经调整净利约5.38亿元同比增长约36.5%
《业绩》先声药业(02096.HK)中期纯利4.57亿人民币跌79.9% 不派息
阿斯达克财经 · 08-22
《业绩》先声药业(02096.HK)中期纯利4.57亿人民币跌79.9% 不派息
先声药业(02096)公布中期业绩 经调整净利约5.38亿元 同比增长约36.5%
智通财经 · 08-21
先声药业(02096)公布中期业绩 经调整净利约5.38亿元 同比增长约36.5%
先声药业8月19日注销已回购股份合共1696.9万股
新浪港股 · 08-20
先声药业8月19日注销已回购股份合共1696.9万股
先博生物增资至5795.45万元,背后任晋生家族财富一年缩水近百亿
新浪财经 · 08-19
先博生物增资至5795.45万元,背后任晋生家族财富一年缩水近百亿
先声药业(02096)8月19日注销已回购股份合共1696.9万股
智通财经 · 08-19
先声药业(02096)8月19日注销已回购股份合共1696.9万股
“福布斯富豪”押注新冠特效药,赶上了晚集!
野马财经 · 08-16
“福布斯富豪”押注新冠特效药,赶上了晚集!
下周备忘
阿斯达克财经 · 08-16
下周备忘
先声药业被投资带崩业绩,任晋生家族财富1年缩水近百亿
蓝鲸财经 · 08-13
先声药业被投资带崩业绩,任晋生家族财富1年缩水近百亿
爆了!突发大涨
格隆汇 · 08-12
爆了!突发大涨
港股概念追踪 |中国科学家揭示新冠病毒进化方向 治疗药物产业链受关注(附概念股)
智通财经 · 08-12
港股概念追踪 |中国科学家揭示新冠病毒进化方向 治疗药物产业链受关注(附概念股)
港股异动 | 先声药业(02096)盘中涨近5% 公司称抗新冠创新药先诺欣发货量持续增长
智通财经 · 08-12
港股异动 | 先声药业(02096)盘中涨近5% 公司称抗新冠创新药先诺欣发货量持续增长
加载更多
公司概况
公司名称:
先声药业
所属市场:
SEHK
上市日期:
--
主营业务:
先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药,包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药,比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。
发行价格:
--
{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":5.28,"timestamp":1724400507028,"preClose":5.24,"halted":0,"volume":3793000,"delay":0,"floatShares":2526816618,"shares":2543785618,"eps":0.30026525,"marketStatus":"休市中","marketStatusCode":7,"change":0.04,"latestTime":"08-23 16:08:27","open":5.3,"high":5.3,"low":5.08,"amount":19671760,"amplitude":0.041985,"askPrice":5.28,"askSize":429000,"bidPrice":5.23,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":-0.47445125209920247,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"listingDate":1603728000000,"adjPreClose":5.24,"dividendRate":0.033207,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":2.1927390449002404,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096","defaultTab":"news","newsList":[{"id":"2462588610","title":"先声药业(02096.HK):1H24经调整利润略超预期 关注创新放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2462588610","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462588610?lang=zh_cn&edition=full","pubTime":"2024-08-25 12:51","pubTimestamp":1724561516,"startTime":"0","endTime":"0","summary":"由于研发费用节约良好,1H24 经调整净利润略超我们的预期。关注近期创新产品放量情况。其中管理层预计先必新舌下片2H24 获批,销售峰值15 亿元;科唯可预计上市后主要聚焦对日间功能和成瘾性要求较高的患者,销售峰值15 亿元。盈利预测与估值考虑公司费用管控良好,上调2024 年经调整净利润预测7%至9.8 亿元,维持2025 年经调整净利润预测11.4 亿元不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408251251589f51c6ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408251251589f51c6ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","BK1583","BK1191"],"gpt_icon":0},{"id":"2461566352","title":"先声药业(02096)8月23日斥资1021.48万港元回购196万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461566352","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461566352?lang=zh_cn&edition=full","pubTime":"2024-08-23 18:24","pubTimestamp":1724408652,"startTime":"0","endTime":"0","summary":"智通财经APP讯,先声药业(02096)发布公告,该公司于2024年8月23日斥资1021.48万港元回购196万股股份,每股回购价格为5.1-5.28港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1191","BK1583"],"gpt_icon":0},{"id":"2461325727","title":"先声药业(02096.HK)抗肿瘤候选药获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2461325727","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461325727?lang=zh_cn&edition=full","pubTime":"2024-08-23 01:36","pubTimestamp":1724348160,"startTime":"0","endTime":"0","summary":"先声药业(02096.HK) 公布,集团自主研发的抗肿瘤候选药物-小分子抑制剂SIM0508已获中国国家药品监督管理局签发的药物临床试验批准通知书,拟开展SIM0508用于晚期实体瘤的临床试验。(de/dZ(港股报价延迟最少十五分钟。沽空资料截至 2024-08-22 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132909636_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132909636_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1374265/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1576","BK1583","03347","02096","BK1141","BK1191"],"gpt_icon":0},{"id":"2461319813","title":"先声药业(02096.HK):SIM0508(Polθ小分子抑制剂)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2461319813","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461319813?lang=zh_cn&edition=full","pubTime":"2024-08-22 20:17","pubTimestamp":1724329049,"startTime":"0","endTime":"0","summary":"格隆汇8月22日丨 先声药业公告,于2024年8月22日,集团自主研发的抗肿瘤候选药物-DNA聚合酶θ小分子抑制剂SIM0508已获得中国国家药品监督管理局签发的药物临床试验批准通知书,拟开展SIM0508用于晚期实体瘤的临床试验。SIM0508在临床前研究中表现出良好的口服药代动力学性质和安全性,未观察到明显的血液学毒性,提示SIM0508与PARP抑制剂或化疗药物联用产生叠加毒性的风险较低。对多种HRD的实体瘤患者而言,SIM0508是一种潜在的有效且安全的治疗新策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822201729ab5f1e0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822201729ab5f1e0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","02096","BK1583","BK1141","03347","BK1191"],"gpt_icon":0},{"id":"2461319856","title":"先声药业(02096)自主研发的抗肿瘤候选药物-DNA聚合酶θ(Polθ)小分子抑制剂SIM0508获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2461319856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461319856?lang=zh_cn&edition=full","pubTime":"2024-08-22 20:15","pubTimestamp":1724328918,"startTime":"0","endTime":"0","summary":"智通财经APP讯,先声药业(02096)公布,于2024年8月22日,该集团自主研发的抗肿瘤候选药物-DNA聚合酶θ(Polθ)小分子抑制剂SIM0508已获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书,拟开展SIM0508用于晚期实体瘤的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["DNA","02096","03347","BK1583","BK1191","BK4139","BK1576","BK1141","BK4109"],"gpt_icon":0},{"id":"2461321392","title":"先声药业(02096)授出合共296.81万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2461321392","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461321392?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:45","pubTimestamp":1724323539,"startTime":"0","endTime":"0","summary":"智通财经APP讯,先声药业(02096)发布公告,于2024年8月2日,其议决根据2021年受限制股份单位计划按零代价向合共98名合资格参与者授出合共296.81万份受限制股份单位,惟须待承授人接纳。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"gpt_icon":0},{"id":"2461380629","title":"港股药品股多数下跌,石药集团(01093.HK)跌超8%,石四药集团(02005.HK)跌超3%,先声药业(02096.HK)、联邦制药(03933.","url":"https://stock-news.laohu8.com/highlight/detail?id=2461380629","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461380629?lang=zh_cn&edition=full","pubTime":"2024-08-22 09:50","pubTimestamp":1724291402,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["YANG","HSTECH","BK1191","07226","BK1583","SG9999004220.SGD","BK1515","02096","LU0326950275.SGD","LU1960683339.HKD","LU0067412154.USD","LU0880133367.SGD","LU1152091754.HKD","01093","LU1152091168.USD","LU1807302812.USD","LU1226287529.USD","IE00B031HY20.USD","LU0501845795.SGD","03933","02005","HSCEI","BK1521","LU0072913022.USD","IE0008368742.USD","IE0008369823.USD","IE00B543WZ88.USD","LU1993786604.SGD","LU0140636845.USD","LU2460026573.USD","LU1008478684.HKD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2461538969","title":"先声药业:2024年上半年收入31.14亿元,同比下降7.9%,创新药业务收入占比70.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461538969","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461538969?lang=zh_cn&edition=full","pubTime":"2024-08-22 08:20","pubTimestamp":1724286018,"startTime":"0","endTime":"0","summary":"先声药业 公告,截至2024年6月30日止六个月,集团收入约31.14亿元,同比下降7.9%; 创新药 业务收入约22.03亿元,占总收入比率约70.7%,同比下降8.7%。归属于公司股东的利润约4.57亿元,同比下降79.9%;经调整归属于公司股东的利润约5.38亿元,同比增长36.5%。截至2024年6月30日,集团收入主要来自肿瘤、神经系统、自身免疫及其他领域,分别为6.19亿元、9.09亿元、8.50亿元和7.36亿元。研发投入总额约6.12亿元,同比减少38.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408220830229f4599c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408220830229f4599c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","06978","BK1574","BK1583","BK1161","BK1191"],"gpt_icon":0},{"id":"2461297800","title":"先声药业公布中期业绩 经调整净利约5.38亿元同比增长约36.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461297800","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461297800?lang=zh_cn&edition=full","pubTime":"2024-08-22 07:11","pubTimestamp":1724281909,"startTime":"0","endTime":"0","summary":"先声药业(02096)公布2024年中期业绩,总收入约人民币31.14亿元,创新药业务收入约人民币22.03亿元。归属于公司权益股东的利润约人民币4.57亿元,经调整归属于公司权益股东的利润约人民币5.38亿元,同比增长约36.5%。\n 在聚焦领域内,该集团有七款创新药获批上市销售。截至2024年6月30日,该集团有14种产品进入100多个政府机构或权威专业学会发布的指南和路径,超过40个产品被纳入国家医保药品目录(NRDL)。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-22/doc-incknhzk1953926.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-22/doc-incknhzk1953926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1191","02096","BK1583"],"gpt_icon":0},{"id":"2461870890","title":"《业绩》先声药业(02096.HK)中期纯利4.57亿人民币跌79.9% 不派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2461870890","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461870890?lang=zh_cn&edition=full","pubTime":"2024-08-22 03:15","pubTimestamp":1724267700,"startTime":"0","endTime":"0","summary":"先声药业(02096.HK) 公布6月止六个月中期业绩,收入31.14亿人民币(下同),按年下降7.9%。录得纯利4.57亿元,倒退79.9%,每股盈利18分。不派中期息。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-21 16:25。)过往派息公布日期派息事项派息内容2024/03/20末期业绩普通股息:人民币 0.16 (相当于港元 0.1757)2023/08/21中期业绩无派息2023/03/31末期业绩普通股息:人民币 0.1600﹙相当于港元 0.17576﹚2022/08/31中期业绩无派息 AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210308110544834_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210308110544834_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1373810/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1583","02096"],"gpt_icon":0},{"id":"2461822454","title":"先声药业(02096)公布中期业绩 经调整净利约5.38亿元 同比增长约36.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461822454","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461822454?lang=zh_cn&edition=full","pubTime":"2024-08-21 22:46","pubTimestamp":1724251570,"startTime":"0","endTime":"0","summary":"智通财经APP讯,先声药业 公布2024年中期业绩,总收入约人民币31.14亿元,创新药业务收入约人民币22.03亿元。归属于公司权益股东的利润约人民币4.57亿元,经调整归属于公司权益股东的利润约人民币5.38亿元,同比增长约36.5%。在聚焦领域内,该集团有七款创新药获批上市销售。截至2024年6月30日,该集团有14种产品进入100多个政府机构或权威专业学会发布的指南和路径,超过40个产品被纳入国家医保药品目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"gpt_icon":0},{"id":"2460092133","title":"先声药业8月19日注销已回购股份合共1696.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2460092133","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460092133?lang=zh_cn&edition=full","pubTime":"2024-08-20 08:33","pubTimestamp":1724114009,"startTime":"0","endTime":"0","summary":"先声药业(02096)发布公告,于2024年8月19日注销已回购股份合共1696.9万股。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-20/doc-inckfzcn0506510.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-20/doc-inckfzcn0506510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1583","BK1191","02096"],"gpt_icon":0},{"id":"2460053124","title":"先博生物增资至5795.45万元,背后任晋生家族财富一年缩水近百亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2460053124","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460053124?lang=zh_cn&edition=full","pubTime":"2024-08-19 22:36","pubTimestamp":1724078217,"startTime":"0","endTime":"0","summary":"工商资料显示,先博生物成立于2021年9月,注册资本5795.45万元,法定代表人为曹卓晓,经营范围含技术服务、生物 化工 产品技术研发;化工产品销售等。另外,先博生物的第二大、第三大股东均有任晋生身影。先声药业发布的业绩预告显示,预计2024年上半年,收入同比下滑约7.0%至8.8%;归属于公司权益股东的利润同比暴跌约78.6%至81.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081922503795a759fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081922503795a759fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","BK1191","BK1583"],"gpt_icon":0},{"id":"2460080299","title":"先声药业(02096)8月19日注销已回购股份合共1696.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2460080299","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460080299?lang=zh_cn&edition=full","pubTime":"2024-08-19 19:52","pubTimestamp":1724068372,"startTime":"0","endTime":"0","summary":"智通财经APP讯,先声药业(02096)发布公告,于2024年8月19日注销已回购股份合共1696.9万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1166485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1583","BK1191"],"gpt_icon":0},{"id":"2459841290","title":"“福布斯富豪”押注新冠特效药,赶上了晚集!","url":"https://stock-news.laohu8.com/highlight/detail?id=2459841290","media":"野马财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459841290?lang=zh_cn&edition=full","pubTime":"2024-08-16 18:49","pubTimestamp":1723805368,"startTime":"0","endTime":"0","summary":"中国疾控中心8月8日发布的全国新冠病毒感染疫情情况显示,全国哨点医院流感样病例新冠病毒阳性率从第27周的8.9%持续上升至第30周的18.7%。广东省疾病预防控制局公布的7月全省法定传染病疫情概况显示,新冠病毒感染共18384例,比6月增加了一万余例。目前,先声药业的业务主要集中在神经系统、肿瘤、自身免疫等领域。新冠业务的重创让众多相关药企一蹶不振,不过也有药企已调整业务重心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408161857549f310cc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408161857549f310cc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","BK1191","BK1583"],"gpt_icon":0},{"id":"2459995972","title":"下周备忘","url":"https://stock-news.laohu8.com/highlight/detail?id=2459995972","media":"阿斯达克财经","labels":["Economic Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459995972?lang=zh_cn&edition=full","pubTime":"2024-08-16 18:05","pubTimestamp":1723802700,"startTime":"0","endTime":"0","summary":"8月19日(周一)新西兰7月央行服务业表现指数:前值40.2日本6月核心机械订单月率:预测转升0.9%;前值跌3.2%日本6月核心机械订单年率:预测升1.1%;前值升10.8%英国8月Rightmove房价指数年率:前值升0.4%英国8月Rightmove房价指数月率:前值跌0.4%美国7月咨商会领先指标:预测跌0.3%;前值跌0.2%业绩公布:恒安国际(01044.HK)、华润啤酒(00291.","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180504113903359_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180504113903359_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1372387&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00425","02410","00081","02778","02899","01033","02380","02869","09979","03311","00173","01070","00548","06098","01816","02096","03668","01071","02057","02018","01224","00511","06969","06979","01530","01044","00386","09992","09690","02688","00780","02367","02480","02382","01833","01962","09997","09698","02878","09969","00097","00069","01036","00388","01368","03808"],"gpt_icon":1},{"id":"2459911447","title":"先声药业被投资带崩业绩,任晋生家族财富1年缩水近百亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2459911447","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459911447?lang=zh_cn&edition=full","pubTime":"2024-08-13 12:24","pubTimestamp":1723523068,"startTime":"0","endTime":"0","summary":"2024年上半年,先声药业将交出一份营收、利润双双下滑的成绩单。先声药业发布的业绩预告显示,预计2024年上半年,收入同比下滑约7.0%至8.8%;归属于公司权益股东的利润同比暴跌约78.6%至81.2%。对于先声药业业绩的下滑,资本市场似乎已经习以为常。《胡润全球富豪榜》榜单显示,2023年到2024年,任晋生家族财富从170亿元滑落至72亿元,短短一年时间,蒸发近百亿。对于收入的下滑,先声药业主要归因于两方面。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/237492","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02096","BK1583","BK1191"],"gpt_icon":0},{"id":"2458600434","title":"爆了!突发大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2458600434","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458600434?lang=zh_cn&edition=full","pubTime":"2024-08-12 20:46","pubTimestamp":1723466764,"startTime":"0","endTime":"0","summary":"催化剂不断","market":"sg","thumbnail":"https://img3.gelonghui.com/59505-aa9de448-c114-47fa-946c-fa675e71c1b5.jpg?guru_height=857&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/59505-aa9de448-c114-47fa-946c-fa675e71c1b5.jpg?guru_height=857&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/920144","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1583","LU0516422440.USD","09939","LU0052750758.USD","02269","159892","LU0588546209.SGD","LU0516422952.EUR","01789","LU0516423174.USD","LU1794554557.SGD","BK1576","BK1515","06978","BK1100","BK1161","LU0456846285.SGD","LU1880383366.USD","LU1242518857.USD","01801","LU2039709279.SGD","LU0327786744.USD","BK1585","LU0043850808.USD","LU0572944931.SGD","01177","LU0359202008.SGD","LU0417516902.SGD","BK1191","LU0823426308.USD","BK1574","LU1969619763.USD","BK1521","FDN","LU0181495838.USD","LU0326950275.SGD","688235","LU0348735423.USD","LU0348825331.USD","LU0823426480.USD","LU0708995583.HKD","BK1589","02096","LU0456827905.SGD","LU1720050803.USD","LU0307460666.USD","BK1610","LU0359201612.USD","LU0516423091.SGD","LU0979878070.USD"],"gpt_icon":0},{"id":"2458762137","title":"港股概念追踪 |中国科学家揭示新冠病毒进化方向 治疗药物产业链受关注(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2458762137","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458762137?lang=zh_cn&edition=full","pubTime":"2024-08-12 14:04","pubTimestamp":1723442684,"startTime":"0","endTime":"0","summary":"广东省疾病预防控制局公布的2024年6月和7月全省法定传染病疫情概况显示,6月份广东省新冠病毒感染发病数为8246,7月份为18384,增加了1万余病例。从长期来看,新冠病毒对宿主的致病性可能正在减弱。自2019年底首次被发现以来,新冠病毒通过一系列突变不断适应宿主环境,显著提高了传播力。此前,该联合团队揭示了新冠病毒的糖基化修饰促进了病毒“温和化”,使其向着类似引起普通感冒的冠状病毒方向演化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","BK1583","HSCEI","HSTECH","06185","BK1574","YANG","BK1515","BK1191","BK1161","02096"],"gpt_icon":1},{"id":"2458629521","title":"港股异动 | 先声药业(02096)盘中涨近5% 公司称抗新冠创新药先诺欣发货量持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2458629521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458629521?lang=zh_cn&edition=full","pubTime":"2024-08-12 13:48","pubTimestamp":1723441703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,先声药业盘中涨近5%,截至发稿,涨3.72%,报5.57港元,成交额1826.38万港元。此外,据中疾控日前发布的2024年7月数据显示,新冠感染人数占比升高。据财联社报道,先声药业表示,从上个月开始,公司抗新冠药先诺欣的发货量就开始增长,本月延续增长。据悉,先声药业的先诺欣是国内首款获得常规批准的口服抗新冠病毒药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1583","BK1191","BK1574","02096","06978","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":-0.0469},{"period":"1month","weight":-0.0204},{"period":"3month","weight":-0.0319},{"period":"6month","weight":-0.0197},{"period":"1year","weight":-0.1694},{"period":"ytd","weight":-0.1915}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药,包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药,比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.125153},{"month":2,"riseRate":0.5,"avgChangeRate":0.05159},{"month":3,"riseRate":0.5,"avgChangeRate":-0.025896},{"month":4,"riseRate":0.5,"avgChangeRate":-0.016117},{"month":5,"riseRate":0.75,"avgChangeRate":0.081955},{"month":6,"riseRate":0.75,"avgChangeRate":0.075768},{"month":7,"riseRate":0,"avgChangeRate":-0.112762},{"month":8,"riseRate":0,"avgChangeRate":-0.110134},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.070612},{"month":10,"riseRate":1,"avgChangeRate":0.178951},{"month":11,"riseRate":0.75,"avgChangeRate":0.041198},{"month":12,"riseRate":0.5,"avgChangeRate":0.027871}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}